Bastian 2012.

Methods	Setting: USA Recruitment: participants identified from electronic medical records. Eligibility assessment in person and selected for motivation to quit
Participants	471 smoker; 8.5% female, average age 59; heaviness of smoking index mean 2.8 Therapists: masters‐level counsellors with training
Interventions	Pharmacotherapy: NRT; inhaler, patch, spray and/or bupropion (regimen and dosage dependent on the number of cigarettes smoked per day and tobacco cessation anxiety) 1. Usual care: 5 telephone sessions every 3‐4 weeks; each session lasting 20 minutes 2. Family‐supported 5 telephone sessions every 3‐4 weeks; each session lasting 20 minutes
Outcomes	7‐day point prevalence abstinence at 5 and 12 months Validation: attempted verification by mailing saliva‐sampling kits to test for cotinine level but the return rates were low (50.5%)
Source of Funding/CoI	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Health Services Research and Development. Authors declared a consultancy to Gilead Sciences and Watermark Research Partners.
Notes	New for 2019 update
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Low rates of return when biochemical validation was attempted, but contact‐matched so differential misreport judged unlikely
Incomplete outcome data (attrition bias) All outcomes	Low risk	21.7 to 28.4% lost to follow‐up rate